Financial Data and Key Metrics Changes - Fourth quarter consolidated revenue increased 15% year-over-year to $638 million, nearing the high end of guidance range [64] - Consolidated adjusted EBITDA for the fourth quarter was $94 million, reflecting a $43 million sequential increase [75] - Consolidated net loss per share in the fourth quarter was $23.49, compared to a net loss per share of $0.07 in the same quarter of 2021, primarily due to a noncash goodwill impairment charge of $3.8 billion [3] Business Line Data and Key Metrics Changes - Integrated Care segment revenue grew 6% year-over-year to $357 million, driven by Chronic Care Management and Telemedicine product revenue [1] - BetterHelp segment revenue increased 29% year-over-year in the fourth quarter to $277 million, primarily due to growth in membership [103] - Total Chronic Care program enrollment exceeded 1 million, representing a 16% increase over the prior year's fourth quarter [52] Market Data and Key Metrics Changes - Integrated Care segment U.S. membership increased to 83.3 million, with paid members reaching 58.7 million, exceeding prior guidance [1][4] - For 2023, the company expects Integrated Care segment U.S. membership to reach 84 million to 86 million members [4] - The company anticipates revenue growth of 6% to 11% for the full year 2023, with adjusted EBITDA growth of 12% to 32% [70][78] Company Strategy and Development Direction - The company is focusing on a balanced approach to growth and margin improvement, aiming for GAAP profitability while maintaining sustainable top-line growth [47][68] - Strategic priorities include expanding the whole person suite of services, particularly the Primary360 offering and BetterHelp brand [46][68] - The management is optimizing the cost structure, including layoffs and restructuring, to improve efficiency [45][86] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing economic uncertainty and a moderation in overall market growth rates, but remains optimistic about the demand for integrated virtual care solutions [67][68] - The company is experiencing strong interest in value-based arrangements from health plans, with a fourfold increase in interest year-over-year [83] - Management expects to generate free cash flow of at least $100 million in 2023, driven by growth in adjusted EBITDA and a decline in capitalized software development costs [55] Other Important Information - The company reported a goodwill impairment charge reflecting the overall operating environment and decreased market multiples, which is noncash and does not impact financial position [54] - The company generated free cash flow of $12 million and $17 million for the fourth quarter and full year, respectively, ending the year with $918 million in cash and short-term investments [104] Q&A Session Summary Question: Expectations for BetterHelp user growth - Management indicated that there is a strong long-term growth potential for BetterHelp, with significant year-over-year increases in user base [7] Question: Drivers of margin improvement - Key drivers for margin improvement include leveraging advertising and marketing expenses, technology development expense leverage, and G&A efficiency [10][12] Question: Impact of macroeconomic factors on membership - Management stated that there has not been a significant impact on membership from recent job cuts, although there is a heightened sensitivity to consumer behavior in the BetterHelp segment [26][27] Question: Integration of virtual and physical care - The company emphasized that their Primary360 product serves different purposes than general medical services, and they do not see cannibalization between the two [16] Question: Future growth expectations for Primary360 - Management expects to triple the revenue from Primary360 in 2023 compared to 2022, indicating strong growth potential [87][90]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TELADOC HEALTH, INC. (Exact name of registrant as specified in its charter) 2 Manhattanville Road, Suite 203 Purcha ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TELADOC HEALTH, INC. (Exact name of registrant as specified in its charter) (Address of principal executive office ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2021 8i or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TELADOC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 04-3705970 (State of incorporation) (I ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TELADOC HEALTH, INC. (Exact name of registrant as specified in its charter) 2 Manhattanville Road, Suite 203 P ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TELADOC HEALTH, INC. (Exact name of registrant as specified in its charter) (Registrant's telephone number includin ...

Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TELADOC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 04-3705970 (State of incorpor ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2020 8i or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TELADOC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 04-3705970 (State of incorporation) (I ...

Table of Contents For the transition period from to Commission File Number: 001-37477 TELADOC HEALTH, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) Delaware 04-3705970 (State of inco ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37477 TELADOC HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 04-3705970 (State of incorpora ...